[go: up one dir, main page]

WO1996009399A3 - Chimeric adenovirus for gene delivery - Google Patents

Chimeric adenovirus for gene delivery Download PDF

Info

Publication number
WO1996009399A3
WO1996009399A3 PCT/US1995/011537 US9511537W WO9609399A3 WO 1996009399 A3 WO1996009399 A3 WO 1996009399A3 US 9511537 W US9511537 W US 9511537W WO 9609399 A3 WO9609399 A3 WO 9609399A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric adenovirus
gene delivery
useful
chimeric
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/011537
Other languages
French (fr)
Other versions
WO1996009399A2 (en
Inventor
Srinivas Shankara
Varavani Dwarki
Tarlochan Nijjar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somatix Therapy Corp
Original Assignee
Somatix Therapy Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somatix Therapy Corp filed Critical Somatix Therapy Corp
Priority to AU35511/95A priority Critical patent/AU3551195A/en
Publication of WO1996009399A2 publication Critical patent/WO1996009399A2/en
Publication of WO1996009399A3 publication Critical patent/WO1996009399A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Chimeric adenovirus capable of transducing mammalian cells with DNA of interest are disclosed. The chimeric adenovirus are useful for the delivery of cloned genes into an individual and are therefore also useful for treating mammalian genetic diseases and disorders.
PCT/US1995/011537 1994-09-23 1995-09-12 Chimeric adenovirus for gene delivery Ceased WO1996009399A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35511/95A AU3551195A (en) 1994-09-23 1995-09-12 Chimeric adenovirus for gene delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31148594A 1994-09-23 1994-09-23
US311,485 1994-09-23

Publications (2)

Publication Number Publication Date
WO1996009399A2 WO1996009399A2 (en) 1996-03-28
WO1996009399A3 true WO1996009399A3 (en) 1996-07-18

Family

ID=23207088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/011537 Ceased WO1996009399A2 (en) 1994-09-23 1995-09-12 Chimeric adenovirus for gene delivery

Country Status (2)

Country Link
AU (1) AU3551195A (en)
WO (1) WO1996009399A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
AU7665396A (en) * 1995-10-27 1997-05-15 Trustees Of The University Of Pennsylvania, The Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
FR2741358B1 (en) * 1995-11-17 1998-01-02 Centre Nat Rech Scient PRODUCTION OF RETROVIRAL VECTORS VIA DNA VIRUS-BASED VIRAL VECTORS
CN1244215B (en) * 1996-11-20 2010-11-03 荷兰克鲁塞尔公司 Improved adenovirus vector production and purification methods
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1320621A4 (en) * 2000-09-15 2005-11-23 Merck & Co Inc ADVANCED FIRST-GENE ADENOVIRAL VACCINES EXPRESSING CODON OPTIMIZATION OF THE GAG, POL AND NEF PROTEINS OF HIV-1 AND CHANGES THEREOF
CN100361710C (en) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
CN101080488A (en) 2004-11-03 2007-11-28 因特罗根治疗公司 A new method for the production and purification of adenoviral vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003163A1 (en) * 1991-08-01 1993-02-18 Fondation Nationale De Transfusion Sanguine Expression in non-tumoral human lymphoblastoid lines with an integrative vector

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003163A1 (en) * 1991-08-01 1993-02-18 Fondation Nationale De Transfusion Sanguine Expression in non-tumoral human lymphoblastoid lines with an integrative vector

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.CAILLAUD ET AL.: "Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 5, no. 10, 1 October 1993 (1993-10-01), pages 1287 - 1291, XP002002600 *
S-H CHEN ET AL.: "Gene therapy for brain tumors:Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, 12 April 1994 (1994-04-12), WASHINGTON US, pages 3054 - 3057, XP002002601 *

Also Published As

Publication number Publication date
WO1996009399A2 (en) 1996-03-28
AU3551195A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
WO1997014809A3 (en) Novel expression vectors and methods of use
AU682140B2 (en) Multidrug resistance gene
ZA959598B (en) DNA regulating the gene expression of coryneform bacteria
DE69636866D1 (en) Reverse "two-hybrid"-systeme
WO1993024640A3 (en) Methods and compositions for in vivo gene therapy
AU560340B2 (en) Rennin from recombinant dna
WO2000006705A3 (en) Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
EP0568537A4 (en) Genetic modification of endothelial cells.
WO1996014408A3 (en) Nucleotide sequence encoding the enzyme i-scei and the uses thereof
EP0804609A4 (en) NOVEL p53 RESPONSE GENES
CA2294598A1 (en) Transcriptional activators with graded transactivation potential
CA2228635A1 (en) Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
ATE338821T1 (en) STRUCTURAL PROTEIN OF AAV, ITS PRODUCTION AND USE
AU1265097A (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
CA2285667A1 (en) Viral vectors having chimeric envelope proteins containing the igg-binding domain of protein a
WO1996009399A3 (en) Chimeric adenovirus for gene delivery
EP0848063A3 (en) Nucleic acid constructs containing hybrid promotors for use in gene therapy
WO1998037185A3 (en) Vectors for controlled gene expression
WO2001030992A3 (en) α1-3 GALACTOSYLTRANSFERASE GENE AND PROMOTER
WO1995023855A3 (en) Genes and genetic elements associated with control of neoplastic transformation in mammalian cells
EP0808323A4 (en) MUTANTS OF THE Rb AND p53 GENES AND USES THEREOF
WO1997005241A3 (en) Methods and compositions for identifying morphogen analogs
WO1997005285A3 (en) Methods and compositions for identifying morphogen analogs
AU5318496A (en) Adenovirus vectors for gene therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)